The national drug pricing regulator National Pharmaceutical Pricing Authority (NPPA) has fixed/revised ceiling prices of 55 scheduled formulations of Schedule-I under Drugs (Price Control) Amendment Order, 2016 and Retail Price of 29 formulations under DPCO, 2013 in related Notification /order dated 23.12.2016.

Name of the 55 scheduled formulations for which ceiling prices have been revised are Omeprazole Tablet, Mefenamic acid Tablet, Cefixime Capsule , Metformin Immediate Release Tablet, Metformin Controlled Release Tablet, Diazepam Oral Liquid, N - acetylcysteine Sachet, Tramadol Tablet, Nifedipine Capsule, Lamivudine + Nevirapine + Stavudine Tablet, Halothane Inhalation, Ipratropium Inhalation (MDI/DPI), Ethinylestradiol Tablet, Cytosine Arabinoside Powder for Injection, Salbutamol Oral liquid, Acyclovir Powder for Injection, Vancomycin Powder for Injection, Azithromycin Powder for Injection, Benzathine benzylpenicillin Powder for Injection, Ampicillin Powder for Injection, Amoxicillin + Clavulanic Acid Powder for Injection, Quinine Injection, Etoposide Injection, Cytosine Arabinoside Injection, 5 - Fluorouracil Injection, Methotrexate Injection, Omeprazole Capsule, Hyoscine butylbromide Injection, Diclofenac Injection, Dobutamine Injection, Dopamine Injection, Atracurium Injection, Methylergometrine Injection, Ibuprofen Oral Liquid, Diltiazem Injection, Acyclovir Oral Liquid, Neostigmine Tablet, Nevirapine Oral Liquid, Thiamine Tablet, Glucose Injection, Atropine Ointment, N - acetylcysteine Injection, Thiopentone Powder for Injection, Benzathine Benzylpenicillin Powder for Injection, Midazolam Injection, Sodium Valproate Oral Liquid, Fentanyl Injection, Oxytocin Injection, Domperidone Oral Liquid, Timolol Drops, Midazolam Injection, Ascorbic Acid (Vitamin C).

Name of the 29 formulations for which retail prices have been revised are Candid 3D cream, Fungikind Cream, Oxtiv AP Gel, Adapalene 0.1% w/w and Benzoyl Peroxide 2.5% w/w Gel, Volitra Enzo tablet, Aceclofenac & Paracetamol tablet, Rabeprazole sodium 20mg and Domperidone (SR) 30mg capsule, Enteric coated Pantoprazole sodium 40mg + Domperidone (SR) 30mg capsule, Glimepiride 2mg + Voglibose 0.2mg + Metformin HCl SR 500mg tablet, Glimepiride 1 mg + Voglibose 0.2mg + Metformin HCl SR 500mg tablet, Voglibose 0.2mg + Metformin HCl SR 500mg tablet, Ampoxin CV Forte / Myclav Dry Syrup 457mg/5ml, Sterile water for injection, Paracetamol and Mefenamic Acid Oral suspension, Defenac Injection 75mg/1ml, Xstan -AMH Tablet, Rosuvastatin calcium IP 5mg and Clopidogrel Bisulphate 75mg Capsule, Rosuvastatin calcium IP 10mg and Clopidogrel Bisulphate 75mg Capsule, Nevirapine Extended release tablet, Chorionic Gonadotrophin Injection, Olmetab H tablet, Zyofer XT tablet, Glylim Forte 1 tablet, Gemcitabine injection, Monocef - SB 500mg injection and Voglibose 0.3mg + Metformin HCl SR 500mg tablet (Emvose M 0.3).

Retail price is applicable only to the individual manufacturers/marketeers i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the government under relevant statutes/rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.

The concerned manufacturers of these formulations shall furnish quarterly return to the NPPA, in respect of production/import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturers in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and/or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

In case the retail price of any of the formulations is not complied with, as per instant price notification and notes specified, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

Consequent to the issue of retail price of the formulations as specified in this notification, the price order(s) if any, issued for concerned manufacturer/marketeer prior to said date of notification, stand(s) superseded.